HSBC downgrades Thermo Fisher Scientific stock to Hold on growth concerns

HSBC downgraded Thermo Fisher Scientific (TMO) to Hold from Buy, lowering its price target to $510 from $540, citing concerns over medium-term growth prospects beyond 2027 and underperformance against peers due to factors like NIH funding cuts and pharmaceutical project delays. This cautious stance contrasts with TMO's strong Q2 2025 financial results, which surpassed Wall Street expectations with EPS of $5.36 and revenue of $10.85 billion, leading Bernstein SocGen to raise its price target to $570 while maintaining an Outperform rating. The company also announced the upcoming retirement of its CFO, Stephen Williamson, and the succession of James R. Meyer, adding to the mixed signals regarding its outlook.

Analysis

Thermo Fisher Scientific (TMO) presents a mixed investment case, marked by conflicting analyst ratings and divergent short-term versus medium-term outlooks. HSBC has downgraded the stock to Hold from Buy, cutting its price target to $510, citing a lack of evidence for a structural growth rate exceeding 7% beyond 2027. This caution is supported by the stock's year-to-date underperformance against peers like Danaher (DHR), its vulnerability to NIH funding cuts, and delays in its CRO business, with 14 analysts revising earnings estimates downward. However, this contrasts sharply with TMO's recent strong performance, including a Q2 2025 earnings beat with an EPS of $5.36 on $10.85 billion in revenue, driven by robust growth in pharmaceutical R&D consumables. This performance prompted Bernstein SocGen to reiterate its Outperform rating and raise its price target to $570. From a valuation perspective, the stock trades at a 27.37x P/E ratio, which InvestingPro data suggests is slightly overvalued, while HSBC's target implies a lower 21x P/E on 2026 estimates. The upcoming CFO transition, with an internal promotion, suggests strategic continuity but remains a key governance event to watch.

Key Decisions for Investors

• Investors should monitor for evidence of growth acceleration beyond the mid-single-digit range, as this is the central point of contention between HSBC's cautious Hold rating and Bernstein's more bullish Outperform stance.
• Given that the stock is trading at a P/E of 27.37x and has been flagged as slightly overvalued, consider weighing the strong Q2 2025 earnings beat against the risks of valuation compression if medium-term growth fails to materialize.
• Pay close attention to catalysts such as a recovery in biotech funding and the execution of the planned CFO transition, as these events could significantly influence future sentiment and resolve the current uncertainty in the stock's outlook.